Genscript Biotech Valuation
| GNNSF Stock | USD 1.38 0.01 0.72% |
Today, the firm appears to be overvalued. Genscript Biotech retains a regular Real Value of $1.2 per share. The prevalent price of the firm is $1.38. Our model calculates the value of Genscript Biotech from evaluating the firm fundamentals such as Current Valuation of 5.11 B, return on equity of -0.56, and Return On Asset of -0.12 as well as inspecting its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Genscript Biotech's price fluctuation is very risky at this time. Calculation of the real value of Genscript Biotech is based on 3 months time horizon. Increasing Genscript Biotech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Genscript pink sheet is determined by what a typical buyer is willing to pay for full or partial control of Genscript Biotech. Since Genscript Biotech is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Genscript Pink Sheet. However, Genscript Biotech's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.38 | Real 1.2 | Hype 1.38 | Naive 1.3 |
The real value of Genscript Pink Sheet, also known as its intrinsic value, is the underlying worth of Genscript Biotech Company, which is reflected in its stock price. It is based on Genscript Biotech's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Genscript Biotech's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Genscript Biotech helps investors to forecast how Genscript pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Genscript Biotech more accurately as focusing exclusively on Genscript Biotech's fundamentals will not take into account other important factors: Genscript Biotech Total Value Analysis
Genscript Biotech is currently projected to have takeover price of 5.11 B with market capitalization of 6.67 B, debt of 121.07 M, and cash on hands of 1.26 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Genscript Biotech fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
5.11 B | 6.67 B | 121.07 M | 1.26 B |
Genscript Biotech Investor Information
About 38.0% of the company shares are held by company insiders. The company has Price/Earnings (P/E) ratio of 200.0. Genscript Biotech recorded a loss per share of 0.17. The entity last dividend was issued on the 5th of June 2017. Based on the key indicators obtained from Genscript Biotech's historical financial statements, Genscript Biotech is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December.Genscript Biotech Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Genscript Biotech has an asset utilization ratio of 22.87 percent. This implies that the Company is making $0.23 for each dollar of assets. An increasing asset utilization means that Genscript Biotech is more efficient with each dollar of assets it utilizes for everyday operations.Genscript Biotech Ownership Allocation
Genscript Biotech has a total of 2.12 Billion outstanding shares. Genscript Biotech secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Genscript Biotech Profitability Analysis
The company reported the revenue of 510.6 M. Net Loss for the year was (347.87 M) with profit before overhead, payroll, taxes, and interest of 303.48 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Genscript Biotech's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Genscript Biotech and how it compares across the competition.
About Genscript Biotech Valuation
The pink sheet valuation mechanism determines Genscript Biotech's current worth on a weekly basis. Our valuation model uses a comparative analysis of Genscript Biotech. We calculate exposure to Genscript Biotech's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Genscript Biotech's related companies.Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in North America, Europe, the Peoples Republic of China, Japan, the other Asia Pacific regions, and internationally. Genscript Biotech Corporation was founded in 2002 and is headquartered in Nanjing, the Peoples Republic of China. Genscript Biotech operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 5573 people.
8 Steps to conduct Genscript Biotech's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Genscript Biotech's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Genscript Biotech's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Genscript Biotech's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Genscript Biotech's revenue streams: Identify Genscript Biotech's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Genscript Biotech's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Genscript Biotech's growth potential: Evaluate Genscript Biotech's management, business model, and growth potential.
- Determine Genscript Biotech's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Genscript Biotech's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Genscript Biotech Growth Indicators
Investing in growth stocks can be very risky. If the company such as Genscript Biotech does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 2.1 B | |
| Forward Price Earnings | 79.3651 | |
| Retained Earnings | -522.9 M |
Complementary Tools for Genscript Pink Sheet analysis
When running Genscript Biotech's price analysis, check to measure Genscript Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genscript Biotech is operating at the current time. Most of Genscript Biotech's value examination focuses on studying past and present price action to predict the probability of Genscript Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genscript Biotech's price. Additionally, you may evaluate how the addition of Genscript Biotech to your portfolios can decrease your overall portfolio volatility.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |